fees and expenses incurred in connection with the review and qualification of the offering of the shares of Common Stock by the Financial Industry Regulation Authority, Inc. in an amount not to exceed $15,000. The Underwriters have agreed to reimburse certain of our expenses incurred in connection with this offering.
Option to Purchase Additional Shares of Common Stock
The Selling Securityholders have granted an option to the Underwriters, exercisable for 30 days after the date of this prospectus supplement, to purchase up to 1,200,000 additional shares of Common Stock at the public offering price, less the underwriting discounts and commissions. If the Underwriters exercise this option, each will be obligated, subject to conditions contained in the Underwriting Agreement, to purchase a number of additional shares of Common Stock proportionate to that Underwriter’s initial amount reflected in the above table.
No Sales of Similar Securities
In connection with this offering, we have agreed that for 90 days after the date of this prospectus supplement without first obtaining the written consent of BofA Securities, Inc. and Goldman Sachs & Co. LLC (the “Lock-up Representatives”), we will not, and will not publicly disclose an intention to, without the prior written consent of the Lock-up Representatives, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file or confidentially submit any registration statement under the Securities Act with respect to any of the foregoing or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise (other than (a) the shares of Common Stock to be sold pursuant to the Underwriting Agreement, (b) any shares of Common Stock issued by the Company upon the exercise of an option or warrant or the conversion or exchange of a security outstanding on the date of the Underwriting Agreement and described in this prospectus supplement (including the documents incorporated by reference herein), (c) any shares of Common Stock or restricted stock units or awards issued or options to purchase Common Stock granted pursuant to existing employee benefit plans of the Company described in this prospectus supplement (including the documents incorporated by reference herein), (d) any shares of Common Stock or restricted stock units or awards issued pursuant to any non-employee director stock plan or dividend reinvestment plan described in this prospectus supplement (including the documents incorporated by reference herein), (e) the filing by the Company of a registration statement on Form S-8 covering the registration of any shares of Common Stock or other securities issued under existing employee benefits plan of the Company described in this prospectus supplement (including the documents incorporated by reference herein), (f) the issuance of shares of Common Stock in connection with the acquisition by the Company or any of its subsidiaries of the securities, business, property or other assets of another person or business entity or pursuant to any employee benefit plan assumed by the Company in connection with such acquisition or (g) the issuance of shares of Common Stock, of restricted stock or of options to purchase shares of common stock, in each case, in connection with joint ventures, commercial relationships or other strategic transactions; provided, that the aggregate number of shares of Common Stock that the Company may sell or issue or agree to sell or issue pursuant to this clause (g) does not exceed 10.0% of the total number of shares of Common Stock issued and outstanding immediately following the completion of this offering; and provided, further, that all such recipients of shares of Common Stock will execute and deliver to the Lock-up Representatives, on or prior to such issuance, a lock-up agreement as described in the Underwriting Agreement.
The Selling Securityholders and our executive officers and directors (collectively, the “Lock-Up Parties” and, each, a “Lock-Up Party”) have entered into lock-up agreements whereby they have agreed that for a period of 90 days from the date of this prospectus supplement (the “Lock-Up Period”) they will not and will not publicly disclose an intention to, without the prior written consent of the Lock-up Representatives, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of, any shares of
S-19